Rogaratinib (BAY1163877) + Chemotherapy
Phase 2/3Completed 0 watching 0 views this week📈 Rising
62
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoma, Transitional Cell
Conditions
Carcinoma, Transitional Cell
Trial Timeline
May 31, 2018 → Oct 27, 2020
NCT ID
NCT03410693About Rogaratinib (BAY1163877) + Chemotherapy
Rogaratinib (BAY1163877) + Chemotherapy is a phase 2/3 stage product being developed by Bayer for Carcinoma, Transitional Cell. The current trial status is completed. This product is registered under clinical trial identifier NCT03410693. Target conditions include Carcinoma, Transitional Cell.
Hype Score Breakdown
Clinical
22
Activity
15
Company
7
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03410693 | Phase 2/3 | Completed |
Competing Products
20 competing products in Carcinoma, Transitional Cell